Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epitomics has signed a contract with SAIC Frederick, operating under contract with the National Cancer Institute (NCI) of the US National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) program
Subscribe to our email newsletter
The goal of the project is to develop high affinity and renewable reagents to capture tryptic peptides derived from human plasma protein biomarkers, and then use the captured peptides to quantify the biomarkers by mass spec platforms such as SISCAPA (stable isotope standards and capture by anti-peptide antibodies) and iMALDI (immuno-Matrix-assisted laser desorption/ionization) assays.
Epitomics has completed the first phase of the project to generate and affinity purify rabbit polyclonal antibodies against these biomarkers.
The current project is the continuation into Phase II which involves developing rabbit monoclonal antibodies against selected biomarkers that have been validated in Phase I.
Epitomics CEO Guo-Liang Yu said they are excited to be working with the NCI and look forward to developing quality antibodies that will be key tools in their ongoing research activities.